Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,535,143 shares of the medical research company's stock after selling 159,095 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main owned about 0.40% of Thermo Fisher Scientific worth $798,627,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in TMO. Barrett & Company Inc. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $28,000. FPC Investment Advisory Inc. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth $28,000. Pillar Financial Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $29,000. Missouri Trust & Investment Co purchased a new position in Thermo Fisher Scientific during the 4th quarter worth $29,000. Finally, Endeavor Private Wealth Inc. purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at about $30,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of recent analyst reports. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Stifel Nicolaus lowered their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Evercore ISI decreased their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Raymond James reiterated an "outperform" rating and set a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Finally, Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $607.43.

Thermo Fisher Scientific Trading Down 1.9 %

TMO stock traded down $7.85 during mid-day trading on Friday, hitting $402.93. 2,318,607 shares of the company were exchanged, compared to its average volume of 1,799,554. The business has a fifty day simple moving average of $464.67 and a 200-day simple moving average of $515.28. The firm has a market capitalization of $152.10 billion, a P/E ratio of 24.38, a PEG ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 12-month low of $401.75 and a 12-month high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter last year, the firm earned $5.11 EPS. The firm's revenue for the quarter was up .2% on a year-over-year basis. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were paid a $0.43 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.